Diagnosis and Staging of Large Cell Lymphoma

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common types of lymphoma, accounting for 31% of all non-Hodgkin’s diagnoses. Approximately 79% of cases are B-cell cancers, 16% are T-cell cancers, and the remaining 5% come from an unidentifiable origin. These diseases often affect the elderly population, but they can also affect children.

Large Cell Lymphomas are grouped and classified together because of similarities in the cell mutations and markers. They also present with the same types of symptoms such as fatigue, weakness, weight loss, night sweats, and swollen lymph nodes.

Since these cancers are typically aggressive, they can spread to many different areas in the body. Tumors may develop either in the lymph nodes or other lymph tissue and then spread to the bone, central nervous system, liver, lungs, spleen, testes, thyroid, or gastrointestinal tract.

Diagnosis and Staging of Large Cell Lymphoma

Diagnosis and staging differs slightly for each subtype of LCL. However, blood work, bone marrow biopsies, X-rays, CT scans, PET scans, and ultrasounds may be used for diagnosis and staging in all cases. Staging depends on the location and spread of the disease, with the lower stages typically contained in one area of the lymph nodes and the later stages marked by spread throughout the body.

For more information on large cell lymphomas see the following:

Photo: Pexels

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap